Hypopharyngeal Squamous Cell Carcinoma

Details 253 Trials 13 Therapies

A squamous cell carcinoma arising from the hypopharynx. Signs and symptoms include dysphagia, hemoptysis, and the presence of a neck mass.

parent conditions

Hypopharyngeal Carcinoma

Pharyngeal Squamous Cell Carcinoma

synonyms

Hypopharyngeal Epidermoid Carcinoma

Epidermoid Carcinoma of Hypopharynx

Hypopharyngeal Squamous Cell Carcinoma

Squamous Cell Carcinoma of Hypopharynx

Epidermoid Carcinoma of the Hypopharynx

Hypopharyngeal Throat Squamous Cell Cancer

Squamous Cell Carcinoma of the Hypopharynx

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

179 sites for NCT04590963

Head and Neck Squamous Cell Carcinoma

cetuximab, +1 more drug

immunotherapy, +1 more type

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

151 sites for NCT03765918

Head and Neck Squamous Cell Carcinoma

cisplatin, +2 more drugs

chemotherapy, +2 more types

A Study of Debio 1143 (Xevinapant) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

221 sites for NCT04459715

HPV Negative

Hypopharyngeal Squamous Cell Carcinoma, +2 more conditions

cisplatin, +2 more drugs

chemotherapy, +2 more types

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)

128 sites for NCT04199104

Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions

lenvatinib, +1 more drug

immunotherapy, +1 more type

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

78 sites for NCT02693535

AKT1 Mutation, +128 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +19 more conditions

abemaciclib, +23 more drugs

immunotherapy, +1 more type

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

225 sites for NCT01810913

HPV Negative

Hypopharyngeal Carcinoma, +3 more conditions

atezolizumab, +4 more drugs

chemotherapy, +3 more types

Show 253 Trials for Hypopharyngeal Squamous Cell Carcinoma

pembrolizumab

PD-L1 Expression (CPS >= 1)

Head and Neck Squamous Cell Carcinoma